Article Details
Retrieved on: 2025-04-21 19:12:34
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses a study showing that using nirmatrelvir-ritonavir (Paxlovid), a CYP3A4 inhibitor, reduces stroke and death risks in COVID-19 patients. This aligns with the key concept 'COVID' and tags on drug development.
Article found on: www.cidrap.umn.edu
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here